Medicare Law Causes Roche To Hesitate On Oncology Price Increases
Executive Summary
Roche and Genentech are holding off on price increases in their oncology portfolio to avoid causing more confusion about reimbursement rates, Roche said
You may also be interested in...
Genentech Plans Herceptin Filing In Adjuvant Setting; Survival Benefit Shown
Genentech is preparing to submit a supplemental BLA for Herceptin for the adjuvant treatment of early-stage HER-2 positive breast cancer based on positive interim results from Phase III studies
Genentech Plans Herceptin Filing In Adjuvant Setting; Survival Benefit Shown
Genentech is preparing to submit a supplemental BLA for Herceptin for the adjuvant treatment of early-stage HER-2 positive breast cancer based on positive interim results from Phase III studies
Medicaid “Best Price” Should Guide Medicare ASP Calculations, CMS Says
The Centers for Medicare & Medicaid Services is advising pharmaceutical manufacturers to look at Medicaid "best price" reporting requirements for guidance when calculating "average sales price" for Medicare Part B drugs